Meeting
2023 ASCO Annual Meeting
Implementation of universal pan-cancer germline genetic testing in an Arab population: The Jordanian Exploratory Cancer Genetics (Jo-ECAG) study.
Authors
Hikmat Abdel-Razeq
King Hussein Cancer Center, Amman, Jordan
Hikmat Abdel-Razeq , Sarah M. Nielsen , Abdelghani Tbakhi , Hira Bani Hani , Baha' Sharaf , Ramiz Abu Hijlih , Mais Alkyam , Khansa Al-Azzam , Shatha Elemian , Areej Al-Atary , Malek Horani , Zeidan Zeidan , Abdulla Alzibdeh , Emily M. Russell , Brandie Heald , Robert Luke Nussbaum , Edward D. Esplin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Prevention, Risk Reduction, and Hereditary Cancer
Track
Prevention, Risk Reduction, and Genetics
Sub Track
Germline Genetic Testing
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 10591)
DOI
10.1200/JCO.2023.41.16_suppl.10591
Abstract #
10591
Poster Bd #
224
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Management impact of preoperative germline genetic testing in patients with breast cancer at the Lifespan Cancer Institute.
First Author: Kaitlyn P. Lew
Poster
2020 ASCO Virtual Scientific Program
Effect of genetic testing results on patient-reported quality of life among patients undergoing panel testing for newly diagnosed ovarian cancer.
First Author: Sarah S. Lee
Poster
2024 ASCO Gastrointestinal Cancers Symposium
BXQ-350: A phase 1b/2 placebo controlled, double blinded study on the efficacy and safety of BXQ-350 in combination with mFOLFOX7 and bevacizumab in newly diagnosed metastatic colorectal carcinoma (mCRC).
First Author: Reema Anil Patel
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Impact of the COVID-19 pandemic on colorectal cancer stage at presentation.
First Author: Malcolm Hart Squires III